Interpace Diagnostics to Maintain PancraGEN Availability
Interpace Diagnostics, a key player in the field of genetic testing, has recently made an important announcement regarding its PancraGEN assay. The company's decision to continue offering this critical diagnostic test comes in light of new directives from the Centers for Medicare & Medicaid Services (CMS), which have postponed the implementation of the Genetic Testing for Oncology Local Coverage Determination (LCD).
What is PancraGEN?
PancraGEN is an innovative molecular diagnostic test designed to assess the risk of pancreatic cyst progression to cancer. This test integrates the results of various first-line tests with molecular data to help physicians distinguish between high and low malignancy potential in pancreatic cysts. The insights provided by PancraGEN aid doctors in recommending appropriate treatments, potentially reducing the need for unnecessary surgeries.
The Importance of Coverage
Medicare has consistently covered PancraGEN for over a decade under a specific coverage determination. With the recent delay in policy changes until mid-2025, the opportunity arises for further evaluation of the clinical evidence supporting PancraGEN, ensuring its availability remains intact for physicians and patients.
Company Commitment to Patient Care
Tom Burnell, President and CEO of Interpace, expressed gratitude regarding the pause in the implementation of the LCD, emphasizing the significance of this decision for both physicians and patients. Despite any varying conditions, he reaffirmed the company's commitment to ensuring patients' access to effective diagnostic tools and supporting their healthcare needs.
Operational Sustainability and Job Security
It is essential to note that while Interpace has other testing solutions in its portfolio, specifically for thyroid nodules, such as ThyGeNEXT and ThyraMIR, the extension of PancraGEN availability safeguards numerous jobs within the company. The ongoing service of PancraGEN not only supports patient care but also fosters employment stability for staff involved in specimen processing.
The Future of Interpace Diagnostics
Burnell highlighted the organization’s ongoing journey towards enhancing patient diagnostics through impactful tests like PancraGEN. The company is also focused on collaboration with healthcare authorities to establish robust evidence supporting the continued approval and reimbursement of PancraGEN. This solidarity showcases Interpace's dedication to the advancement of personalized medicine and patient-centered care.
About Interpace Biosciences
Interpace Biosciences is positioning itself as a leader in personalized medicine, offering specialized services that span from early diagnosis to targeted therapeutic applications. The organization provides clinically useful molecular diagnostic tests that help evaluate cancer risk, utilizing cutting-edge technology to improve patient outcomes.
Enabled Services and Tests
The company has commercialized several molecular diagnostic tests, including PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR, and RespriDX, among others. Each of these tests plays a pivotal role in diagnosing and managing various cancers, illustrating Interpace's comprehensive approach to patient care and its commitment to innovation in the healthcare landscape.
Frequently Asked Questions
What is PancraGEN used for?
PancraGEN is used to assess the risk of pancreatic cysts progressing to cancer by providing insights into malignancy potential, aiding in treatment decisions.
Why was the implementation of the LCD postponed?
The implementation of the proposed policy changes was postponed to allow further review by the incoming administration and assess clinical evidence.
How long has PancraGEN been covered by Medicare?
PancraGEN has been continuously covered by Medicare for over a decade, demonstrating its established role in patient care.
How does this affect Interpace's employees?
The decision to continue offering PancraGEN helps secure jobs for many employees involved in processing specimens at Interpace.
What other tests does Interpace offer?
Interpace offers various tests, including ThyGeNEXT for thyroid cancer diagnosis and RespriDX for differentiating lung cancer origins.
